JP4191825B2 - ５−アミノイソキサゾール誘導体 - Google Patents

５−アミノイソキサゾール誘導体 Download PDF

Info

Publication number
JP4191825B2
JP4191825B2 JP27246798A JP27246798A JP4191825B2 JP 4191825 B2 JP4191825 B2 JP 4191825B2 JP 27246798 A JP27246798 A JP 27246798A JP 27246798 A JP27246798 A JP 27246798A JP 4191825 B2 JP4191825 B2 JP 4191825B2
Authority
JP
Japan
Prior art keywords
group
isoxazole
pyridyl
fluorophenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP27246798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000086657A (ja
JP2000086657A5 (https=
Inventor
信義 南
通隆 佐藤
幸市 蓮見
則夫 山本
勝幸 慶野
照明 松井
有弘 金田
修治 太田
教久 斎藤
秀一郎 佐藤
章 朝烏
知 土井
基博 小林
潤 佐藤
創 浅野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Priority to JP27246798A priority Critical patent/JP4191825B2/ja
Publication of JP2000086657A publication Critical patent/JP2000086657A/ja
Publication of JP2000086657A5 publication Critical patent/JP2000086657A5/ja
Application granted granted Critical
Publication of JP4191825B2 publication Critical patent/JP4191825B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP27246798A 1998-09-10 1998-09-10 ５−アミノイソキサゾール誘導体 Expired - Lifetime JP4191825B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP27246798A JP4191825B2 (ja) 1998-09-10 1998-09-10 ５−アミノイソキサゾール誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27246798A JP4191825B2 (ja) 1998-09-10 1998-09-10 ５−アミノイソキサゾール誘導体

Publications (3)

Publication Number Publication Date
JP2000086657A JP2000086657A (ja) 2000-03-28
JP2000086657A5 JP2000086657A5 (https=) 2005-10-20
JP4191825B2 true JP4191825B2 (ja) 2008-12-03

Family

ID=17514333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP27246798A Expired - Lifetime JP4191825B2 (ja) 1998-09-10 1998-09-10 ５−アミノイソキサゾール誘導体

Country Status (1)

Country Link
JP (1) JP4191825B2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420042A1 (en) 2000-08-22 2003-02-18 Mikio Ogawa Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
EP1314719A4 (en) * 2000-09-01 2005-09-21 Ono Pharmaceutical Co Benzoic acid derivatives and medicaments containing them as active ingredients
ATE335737T1 (de) 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc (HALO-BENZO-CARBONYL) HETEROCYCLO-CONDENSED PHENYL-P38-KINASE INHIBITING AGENTS
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE60310730T2 (de) 2002-07-09 2007-05-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
KR20070085371A (ko) 2004-10-16 2007-08-27 아스트라제네카 아베 페녹시 벤즈아미드 화합물의 제조 방법
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2005320544B2 (en) * 2004-12-28 2011-03-24 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazol derivative
NZ560712A (en) 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
PT1975158E (pt) * 2005-12-27 2011-09-23 Ct Nac Investigaciones Oncologicas Cnio Novos derivados de pirrole com actividade inibidora de histona desacetilase
EP2036905B1 (en) * 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
WO2008001929A1 (en) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treatment agent for inflammatory bowel disease
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
UY30822A1 (es) 2006-12-21 2008-07-31 Astrazeneca Ab Fnueva forma cristalina de 3-{[5-azetidin-1-ylcabonyl)pyrazin-2-yl]oxy}-5-[1-methylethyloxy]-n-1h-pyrazol-3-ylbenzamida, composiciones conteniéndola, procesos de preparacion y aplicaciones
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
AR067329A1 (es) * 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用

Also Published As

Publication number Publication date
JP2000086657A (ja) 2000-03-28

Similar Documents

Publication Publication Date Title
JP4191825B2 (ja) ５−アミノイソキサゾール誘導体
JP4632544B2 (ja) アミノピラゾール誘導体
KR102420262B1 (ko) 신규한 퀘르세틴 리독스 유도체 및 bet 억제제로서의 용도
KR102420263B1 (ko) 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도
JP5119157B2 (ja) カゼインキナーゼｉｉ（ｃｋ２）モジュレーターとしてのピラゾロ−ピリミジン類
US8877944B2 (en) 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors
JPWO2000039116A1 (ja) アミノピラゾール誘導体
JPH11335375A (ja) ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
JP5634263B2 (ja) キナゾリンジオンキマーゼ阻害剤
KR102404865B1 (ko) 항종양제
JP2015071622A (ja) 医薬品
WO2016057779A2 (en) Induction of gata2 by hdac1 and hdac2 inhibitors
JP2010508288A (ja) キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
US9120780B2 (en) Indole or indazole derivative or salt thereof
JP2005519074A (ja) 治療用の置換インダゾール誘導体
JP2002088073A (ja) 抗アンドロゲン剤
JP5244591B2 (ja) ピリジルイソオキサゾール誘導体
WO2016120850A9 (en) Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
JPWO2009123080A1 (ja) インドリノン化合物
US20250221977A1 (en) Novel benzothiophene derivative and use thereof as bet inhibitor
ES2609459T3 (es) Compuestos heterocíclicos condensados y su uso
JPWO2008001929A1 (ja) 炎症性腸疾患の処置剤
JP4550353B2 (ja) 造血器型プロスタグランジンｄ２合成酵素阻害剤
CN115784991B (zh) N-(苯磺酰基)酰胺衍生物及其制备方法和用途
JP5424187B2 (ja) アシルアミノフェニル基を有する抗がん剤

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050620

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20080618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080624

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080818

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080916

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080919

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110926

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120926

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120926

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130926

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term